Cara Therapeutics, Inc.
NASDAQ:CARA
0.3 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cara Therapeutics, Inc. |
Symbool | CARA |
Munteenheid | USD |
Prijs | 0.297 |
Beurswaarde | 16,289,440 |
Dividendpercentage | 0% |
52-weken bereik | 0.24 - 1.4 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Christopher A. Posner |
Website | https://www.caratherapeutics.com |
An error occurred while fetching data.
Over Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)